Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Boehringer Ingelheim
Express Scripts
Chinese Patent Office

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,060,634

« Back to Dashboard

Summary for Patent: 4,060,634

Title: Rapidly resorbable glibenclamide
Abstract:A blood sugar lowering composition comprising as the active material particulate glibenclamide having a surface area of about 3 to 10 m.sup.2 /g in admixture with a pharmacologically acceptable non-ionic wetting agent present in about 2 to 20 times the weight of the glibenclamide. The preferred wetting agent is polyoxyethylene stearate present in about 5 to 10 times the weight of the glibenclamide.
Inventor(s): Rothe; Werner (Hockenheim, DT), Heinemann; Helmut (Heidelberg, DT), Schmidt; Felix Helmut (Mannheim-Seckenheim, DT), Betzien; Gunter (Mannheim, DT)
Assignee: Boehringer Mannheim G.m.b.H. (Mannheim, DT)
Application Number:05/688,435
Patent Claim Types:
see list of patent claims
Composition; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,060,634

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
2348334Sep 26, 1973

International Patent Family for Patent: 4,060,634

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria330954► Subscribe
AustriaA762374► Subscribe
Australia7365374► Subscribe
Belgium820254► Subscribe
Canada1029661► Subscribe
Germany2348334► Subscribe
Finland275574► Subscribe
Finland58068► Subscribe
France2244455► Subscribe
United Kingdom1420907► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Farmers Insurance
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: